Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 443

Similar articles for PubMed (Select 18772048)

1.

Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.

Steeves TD, Fox SH.

Prog Brain Res. 2008;172:495-513. doi: 10.1016/S0079-6123(08)00924-2. Review.

PMID:
18772048
2.

[Tourette syndrome. Genetics, neuroanatomy and neurotransmitters].

Debes NM, Skov L, Hjalgrim H.

Ugeskr Laeger. 2008 Aug 25;170(35):2695-700. Review. Danish.

PMID:
18761860
3.

[Tics and Gilles de la Tourette syndrome].

Tijero-Merino B, Gómez-Esteban JC, Zarranz JJ.

Rev Neurol. 2009 Jan 23;48 Suppl 1:S17-20. Review. Spanish.

4.

Extrastriatal dopaminergic dysfunction in tourette syndrome.

Steeves TD, Ko JH, Kideckel DM, Rusjan P, Houle S, Sandor P, Lang AE, Strafella AP.

Ann Neurol. 2010 Feb;67(2):170-81. doi: 10.1002/ana.21809.

PMID:
20225192
5.

Recent advances in Gilles de la Tourette syndrome: implications for clinical practice and future research.

Leckman JF, Cohen DJ.

Psychiatr Dev. 1983 Autumn;1(3):301-16. Review.

PMID:
6324164
6.

Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome.

Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM.

Acta Psychiatr Scand. 1998 Dec;98(6):502-6.

PMID:
9879795
7.

Basal Ganglia volumes in patients with Gilles de la Tourette syndrome.

Peterson BS, Thomas P, Kane MJ, Scahill L, Zhang H, Bronen R, King RA, Leckman JF, Staib L.

Arch Gen Psychiatry. 2003 Apr;60(4):415-24.

PMID:
12695320
8.

Tourette's syndrome and role of tetrabenazine: review and personal experience.

Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D.

Clin Drug Investig. 2008;28(7):443-59. Review.

PMID:
18544005
9.

Distinct structural changes underpin clinical phenotypes in patients with Gilles de la Tourette syndrome.

Worbe Y, Gerardin E, Hartmann A, Valabrégue R, Chupin M, Tremblay L, Vidailhet M, Colliot O, Lehéricy S.

Brain. 2010 Dec;133(Pt 12):3649-60. doi: 10.1093/brain/awq293. Epub 2010 Oct 19.

10.

Transcranial magnetic stimulation in Gilles de la Tourette syndrome.

Orth M.

J Psychosom Res. 2009 Dec;67(6):591-8. doi: 10.1016/j.jpsychores.2009.07.014. Review.

PMID:
19913663
11.

Gilles de la Tourette syndrome and the neurological basis of obsessions and compulsions.

Cummings JL, Frankel M.

Biol Psychiatry. 1985 Oct;20(10):117-26.

PMID:
3862431
12.
13.

Serotonin transporter binding in Tourette Syndrome.

Müller-Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brücke T, Berding G.

Neurosci Lett. 2005 Sep 9;385(2):120-5.

PMID:
15936877
14.

Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Wong DF, Brasić JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA.

Neuropsychopharmacology. 2008 May;33(6):1239-51. Epub 2007 Nov 7.

15.

Tourette syndrome: the self under siege.

Leckman JF, Bloch MH, Scahill L, King RA.

J Child Neurol. 2006 Aug;21(8):642-9. Review.

PMID:
16970864
16.

Tourette syndrome: clinical characteristics and current management strategies.

Kossoff EH, Singer HS.

Paediatr Drugs. 2001;3(5):355-63. Review.

PMID:
11393328
17.

Gilles de la Tourette syndrome.

Suchowersky O.

Can J Neurol Sci. 1994 Feb;21(1):48-52. Review.

PMID:
8180905
18.
19.

[Tics and Tourette syndrome: diagnosis, course and treatment principles].

Houeto JL, Giré P.

Presse Med. 2008 Feb;37(2 Pt 2):263-70. doi: 10.1016/j.lpm.2007.11.007. Epub 2008 Jan 10. Review. French.

PMID:
18191532
20.

Pathophysiology and treatment of secondary obsessive-compulsive behaviors and tics.

Bhangoo RK.

Semin Clin Neuropsychiatry. 2000 Oct;5(4):250-8. Review.

PMID:
11291021
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk